Texas Lawmakers Examined Gaps in Menopause Care
A state subcommittee explored how training and provider awareness affect the care women receive during midlife.
Updated on Oct. 6, 2026 in Women’s Health
Live Poll
Do you trust that medical professionals in your area are properly trained to treat menopause?
The Texas House subcommittee on Maternal Health, Menopause and Access to Evidence-Based Medicine held an interim hearing to address barriers in patient care. The session focused on the persistent lack of standardized training for medical professionals treating menopausal women.
Why it matters
Lawmakers are investigating these systemic gaps because many women report that symptoms are frequently dismissed by clinicians. This focus aims to bridge the divide between modern evidence-based practices and outdated medical school training.
A survey of OB/GYN residency program directors found that 93% support a standardized menopause curriculum, yet only 31% of programs currently provide one. Data also shows that 60% of women report having their symptoms dismissed, with 40% receiving no guidance on treatment.
The players
Texas House subcommittee on Maternal Health, Menopause and Access to Evidence-Based Medicine
A legislative body focused on evaluating access to and the quality of evidence-based medical care for women in midlife.
Texas A&M Family Medicine Residency
A graduate medical training program that implemented a formal menopause gynecology elective and curriculum.
The details
The hearing featured expert testimony from OB/GYNs and specialists who highlighted a reliance on outdated research in medical education. Practitioners pointed to successful models, such as the elective and curriculum established at the Texas A&M Family Medicine Residency in 2022, as potential pathways for improvement. These efforts coincide with national shifts, such as the FDA beginning to remove black box warnings from hormone therapy labels in February 2026.
Timeline
Texas A&M created its menopause curriculum in 2022.
The FDA began removing hormone therapy black box warnings in February 2026.
The subcommittee on Maternal Health was established in August 2026.
The interim hearing took place on October 5, 2026.
The subcommittee will reconvene for a legislative session in January 2027.
Health Landscape
This legislative inquiry reflects a broader shift to align clinical practice with updated regulatory perspectives on hormone therapy. It marks a significant effort to move beyond the FDA black box warning policy change by addressing the foundational lack of provider training.
If you are experiencing menopausal symptoms, it is worth discussing the latest evidence-based options with your physician to ensure you receive current guidance. Keep in mind that clinical awareness is evolving, and you should advocate for comprehensive support if your concerns are not being met.
The takeaway
The hearing highlights that current medical training often lags behind modern research on menopause. Patients should feel empowered to seek specialists who are current on the latest evidence-based treatment guidelines.
What happens next
The subcommittee is scheduled to reconvene during the legislative session starting in January 2027.
Further reading
For more background on hormonal shifts and midlife wellness, visit the Women’s Health section.
Live Poll
Do you trust that medical professionals in your area are properly trained to treat menopause?
